RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements

https://finance.yahoo.com/news/redhill-biopharmas-talicia-added-medi-110000903.html

Addition of Talicia® by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization is an important expansion of coverage for California patients and continues to increase Talicia's overall unrestricted coverage

Coverage commenced for two million patients in Medi-Cal's FFS plan on October 1st, 2021

Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies

H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Medi-Cal - California's Medicaid Health Care program covering two million patients - has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required, effective October 1, 2021.

Coverage for Talicia commenced for two million patients in Medi-Cal's California FFS plan on October 1, 2021.

"Medi-Cal's addition of Talicia with no prior authorization required is an important step in Talicia's continuing growth and we are pleased that it will be made available to Medi-Cal's 2 million FFS lives," said Rick Scruggs, RedHill's Chief Commercial Officer. "There is growing recognition of the need to employ effective, first-line therapy against H. pylori infections that does not rely on clarithromycin and that patients can tolerate well and adhere to over 14 days of therapy. Talicia meets those criteria."